Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products
US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.
You may also be interested in...
Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products
Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.